EUVIMEDEUVIMED entdecken
Crossref

Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients

Hannes Leupe iD, Sophie-Anne De Buyst, Jeroen Dekervel, Frederik Cleeren, Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Christophe Dooms, Sander Jentjens, Lennert Boeckxstaens, Eric Van Cutsem, Filip Van Herpe, Paul M Clement und 6 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-09 · 53 (11) · 6569-6582

DOI: 10.1007/s00259-026-08020-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 23.06.2026. Verfasst von Hannes Leupe und 17 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Octreotide, Fluorine Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Kom op tegen Kanker, FWO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Fluorine-18-labeled somatostatin receptor (SSTR) tracers are increasingly adopted as an alternative to generator-produced gallium-68 compounds for imaging neuroendocrine neoplasms (NENs). While [¹⁸F]AlF-NOTA-octreotide ([¹⁸F]AlF-OC) has shown comparable or even superior diagnostic performance in controlled clinical studies, real-world evidence remains limited, particularly for underrepresented NEN subtypes. This study evaluates the clinical implementation, biodistribution, and uptake characteristics of [¹⁸F]AlF-OC PET/CT in routine practice across the full NEN spectrum. MATERIALS AND METHODS: In this retrospective single-center analysis, all patients referred for SSTR PET/CT between March 2023 and January 2024 were included. Relevant clinical and demographic data, along with procedural details, were collected. Lesions were segmented semi-automatically using MIM version 7.3.4 and quantitatively assessed. Uptake patterns were analyzed according to tumor grade, primary tumor origin, organ site and clinical indication. RESULTS: A total of 322 scans were performed in 288 patients (median age 64 years). The cohort included 93 Grade 1 (G1), 84 G2, 17 G3 NETs and 3 neuroendocrine carcinomas of gastroenteropancreatic (GEP) or unknown origin, alongside 15 phaeochromocytoma/paraganglioma (PPGL) cases and 40 lung NETs. In total, 4,677 lesions were evaluated. Mean injected activity was 208.5 ± 73.6 MBq with an average uptake time of 121 ± 14 min. G3 NETs demonstrated sufficient uptake (mean SUVmax 19.0), comparable to low-grade NETs. Uptake varied by primary origin, with the highest mean SUVmax values observed in gastric (53.3), sigmoidal (22.0), rectal (20.5), small intestinal (19.1) and pancreatic NETs (17.1). Lung NETs (17.0) also have comparable uptake. Strong tracer avidity was observed in lesions within the liver (19.8) and bone (12.1). Physiological distribution was consistent with known SSTR-expressing tissues. CONCLUSION: This large real-world series confirms that [¹⁸F]AlF-OC PET/CT is a robust and broadly applicable SSTR imaging modality across diverse NEN subtypes, including tumor groups traditionally underrepresented in prospective trials of SSTR tracers. The tracer demonstrates reliable uptake across grades and organ sites, supporting its routine clinical use as a practical, high-throughput alternative to ⁶⁸Ga-labeled SSAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPositron Emission Tomography Computed TomographyOctreotideFluorine RadioisotopesHeterocyclic CompoundsHumansFemaleRetrospective StudiesMiddle AgedMaleAgedAdultTissue DistributionAged, 80 and over

Stichwörter der Autor:innen

Neuroendocrine tumorsPET/CTReal-world dataSSTR PETSomatostatin receptor[18F]AlF-NOTA-octreotide

Substanzen

OctreotideFluorine RadioisotopesHeterocyclic Compounds

Autor:innen und Institutionen

  • Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
  • Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Department of Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Department of Oncology, KU Leuven, Leuven, Belgium.

ORCID-Profile: Hannes Leupe, Christophe M Deroose

Förderung

  • Kom op tegen Kanker
  • FWO

Zitieren

APA

Leupe, H., De Buyst, S. A., Dekervel, J., Cleeren, F., Ahmadi Bidakhvidi, N., Goffin, K., Dooms, C., Jentjens, S., Boeckxstaens, L., Van Cutsem, E., Van Herpe, F., Clement, P. M., Rasschaert, G., Koole, M., Van Laere, K., Bormans, G., Verslype, C., & Deroose, C. M. (2026). Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients. European Journal of Nuclear Medicine and Molecular Imaging, 53(11), 6569-6582. https://doi.org/10.1007/s00259-026-08020-z

Vancouver

Leupe H, De Buyst SA, Dekervel J, Cleeren F, Ahmadi Bidakhvidi N, Goffin K, et al. Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(11):6569-6582. doi:10.1007/s00259-026-08020-z

BibTeX
@article{Leupe2026,
  author = {Leupe, Hannes and De Buyst, Sophie-Anne and Dekervel, Jeroen and Cleeren, Frederik and Ahmadi Bidakhvidi, Niloefar and Goffin, Karolien and Dooms, Christophe and Jentjens, Sander and Boeckxstaens, Lennert and Van Cutsem, Eric and Van Herpe, Filip and Clement, Paul M and Rasschaert, Gertjan and Koole, Michel and Van Laere, Koen and Bormans, Guy and Verslype, Chris and Deroose, Christophe M},
  title = {Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {11},
  pages = {6569--6582},
  doi = {10.1007/s00259-026-08020-z}
}
Kostenlos starten →